Selecting Treatments During an Infectious Disease Pandemic: Chasing the Evidence.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 34399058.
- Also identified by DOI 10.7326/M21-3221 and PMC identifier 8372531.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In their article, Mehta and colleagues describe temporal trends in the use of hydroxychloroquine, remdesivir, and dexamethasone for the treatment of COVID-19 in patients hospitalized in the United States over a 13-month period beginning in February 2020. The editorialists discuss the findings and lessons learned from COVID-19 that will improve how we assess and disseminate emerging data leading to efficient, evidence-based implementation (or deimplementation) of treatment.
Medical subject headings
- Adrenal Cortex Hormones
- Antiviral Agents
- Communicable Diseases
- Evidence-Based Medicine
- Pandemics